Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 11 August 2006
Termination of collaboration with Modex
Oxford BioMedica announced in October 200 that its collaboration in the diabetes field with Modex Therapeutics of Lausanne, Switzerland has been terminated by mutual agreement
Strategically, Modex has decided to discontinue its diabetes programme and focus on its other development programmes There is no financial loss for BioMedica associated with this termination
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
The collaboration, initiated in July 1999, used BioMedica's LentiVector to modify pancreatic b-islet cells.
The vectors have been shown to deliver genes very efficiently to these cells and have met all of the expectations.
BioMedica is currently in discussion with two other companies with interests in diabetes applications.
An exciting opportunity in this field is the application of LentiVector to stem cell engineering approaches.
Professor Alan Kingsman, chief executive, commented: "We are sorry that Modex has moved away from its diabetes programme.
"However, with respect to BioMedica, the Modex programme represented only a minor part of our activities and our other programmes, including the two clinical trials, are progressing very well.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
